LYRA
Lyra Therapeutics, Inc. NASDAQ Listed May 1, 2020$0.44
-32.29%
vs $0.65
Mkt Cap $6.8M
52w Low $0.40
0.1% of range
52w High $27.58
50d MA $1.04
200d MA $4.53
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-2.8x
ROE
269.8%
P/FCF
-0.2x
RSI (14)
44.20
ATR (14)
$0.08
Beta
0.30
50d MA
$1.04
200d MA
$4.53
Avg Volume
71.7K
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
480 Arsenal Way · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -2.59 | 8.00 | +408.9% | 1.34 | -1.5% | -1.5% | -62.5% | +1.0% | -12.0% | +4.5% | — |
| Nov 12, 2025 | AMC | -5.98 | -3.38 | +43.5% | 3.88 | +0.0% | -1.5% | +0.8% | -2.9% | -2.4% | -4.9% | — |
| Aug 12, 2025 | AMC | -5.79 | -5.51 | +4.8% | 6.75 | +1.8% | +8.0% | -2.6% | -0.7% | +3.7% | -3.0% | — |
| May 6, 2025 | AMC | -7.50 | -6.00 | +20.0% | 5.10 | +7.5% | +2.9% | -10.1% | +4.0% | -4.1% | +0.2% | — |
| Mar 13, 2025 | AMC | -0.13 | -0.16 | -23.1% | 8.75 | -2.5% | -1.7% | -4.1% | -3.3% | -0.4% | +4.8% | — |
| Nov 12, 2024 | AMC | -0.23 | -0.18 | +21.7% | 13.75 | -3.6% | -28.1% | -9.0% | -5.6% | -1.2% | +16.5% | — |
| Aug 14, 2024 | AMC | -0.34 | -0.29 | +14.7% | 14.33 | +0.6% | +1.2% | +3.0% | +4.4% | +4.5% | +2.7% | — |
| Apr 30, 2024 | AMC | -0.26 | -0.35 | -34.6% | 258.00 | -2.5% | +1.7% | -11.8% | -13.0% | -87.1% | -19.5% | — |
| Mar 21, 2024 | AMC | -0.33 | -0.22 | +33.3% | 303.50 | +10.5% | +2.8% | -1.3% | -0.5% | +6.5% | -4.7% | — |
| Nov 7, 2023 | AMC | -0.33 | -0.27 | +18.2% | 146.50 | +2.4% | +0.0% | -3.8% | +6.4% | -0.7% | -3.4% | — |
| Aug 8, 2023 | AMC | -0.44 | -0.33 | +25.0% | 161.00 | +0.9% | +2.2% | +1.8% | +6.0% | +2.8% | -1.9% | — |
| May 12, 2023 | AMC | -0.36 | -0.44 | -22.2% | 133.50 | +0.4% | -2.2% | +5.7% | -0.7% | -0.7% | -1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.29 | $7.20 | -1.2% | -2.6% | -0.7% | +3.7% | -3.0% | +2.3% |
| Jun 10 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $18.42 | $17.53 | -4.8% | -15.9% | -12.9% | -12.2% | -4.3% | -0.1% |
| Mar 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.75 | $8.53 | -2.5% | -1.7% | -4.1% | -3.3% | -0.4% | +4.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $14.33 | $14.41 | +0.6% | +1.2% | +3.0% | +4.4% | +4.5% | +2.7% |
| May 7 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $26.08 | $22.00 | -15.6% | -19.5% | -7.2% | -0.8% | -3.6% | -2.7% |
| May 7 | Jefferies | Downgrade | Buy → Hold | — | $26.08 | $22.00 | -15.6% | -19.5% | -7.2% | -0.8% | -3.6% | -2.7% |
| May 6 | BTIG | Downgrade | Buy → Neutral | — | $201.50 | $19.57 | -90.3% | -87.1% | -19.5% | -7.2% | -0.8% | -3.6% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $258.00 | $251.50 | -2.5% | +1.7% | -11.8% | -13.0% | -87.1% | -19.5% |
| Mar 25 | BofA Securities | Maintains | Buy → Buy | — | $312.00 | $315.50 | +1.1% | -1.3% | -0.5% | +6.5% | -4.7% | +0.5% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $303.50 | $335.50 | +10.5% | +2.8% | -1.3% | -0.5% | +6.5% | -4.7% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $195.50 | $195.00 | -0.3% | -0.8% | +1.0% | -3.1% | +1.3% | -5.5% |
| Sep 12 | BofA Securities | Maintains | Buy → Buy | — | $214.00 | $252.00 | +17.8% | +7.5% | +2.0% | +1.1% | -8.2% | +5.1% |
| Feb 7 | BTIG | Maintains | Buy → Buy | — | $135.00 | $133.50 | -1.1% | -0.7% | +0.7% | -1.5% | -3.4% | -1.6% |
| May 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $303.50 | $305.50 | +0.7% | -1.2% | -7.8% | -0.5% | +4.2% | -6.6% |
| May 26 | BofA Securities | Maintains | Buy → Buy | — | $721.50 | $735.00 | +1.9% | +8.7% | +1.7% | -1.9% | +1.4% | +1.4% |
| May 26 | Jefferies | Maintains | Buy → Buy | — | $721.50 | $735.00 | +1.9% | +8.7% | +1.7% | -1.9% | +1.4% | +1.4% |
No insider trades available.
8-K
Lyra Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful one-sentence analysis based on this filing summary, as it contains only technical metadata and reference information without substantive business details or corporate actions.
Apr 17
8-K
Unknown — 8-K Filing
LYRA's lease termination on March 31, 2026, eliminates future rent obligations but requires paying $1.5 million in liquidated damages, reducing near-term cash and improving long-term operating flexibility.
Apr 10
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary contains only technical metadata and schema references without substantive business information or events.
Mar 16
8-K
Lyra Therapeutics, Inc. -- 8-K Filing
Lyra Therapeutics has ceased rent payments and cannot reach agreement with its sublease counterparty, indicating the company is proceeding with liquidation and prioritizing cash preservation over lease obligations.
Feb 27
8-K
Lyra Therapeutics, Inc. -- 8-K Filing
Lyra Therapeutics failed to regain Nasdaq compliance by the December 31, 2025 deadline and Nasdaq denied additional time, putting the company at risk of delisting after laying off its entire workforce.
Feb 6
Institutional (13F) — Top 3
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 668 | $2K | Reduced | Dec 2025 |
| 2 | Comerica Bank | 23 | $71 | — | Dec 2025 |
| 3 | Citigroup Inc | 3 | $9 | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 10
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Investment Grade Bond Fund | 3,639,822 | $4M | Feb 2026 |
| 2 | John Hancock Managed Account Shares Securitized Debt Portfolio | 1,577,256 | $2M | Feb 2026 |
| 3 | American Century Multisector Income ETF | 939,137 | $953K | Feb 2026 |
| 4 | American Century Short Duration Strategic Income ETF | 385,862 | $392K | Feb 2026 |
| 5 | John Hancock Income Securities Trust | 144,482 | $146K | Jan 2026 |
| 6 | Morningstar Total Return Bond Fund | 92,616 | $94K | Jan 2026 |
| 7 | LOW-DURATION BOND FUND | 92,616 | $93K | Mar 2026 |
| 8 | Fidelity Extended Market Index Fund | 9,491 | $10K | Feb 2026 |
| 9 | Fidelity Series Total Market Index Fund | 1,260 | $1K | Feb 2026 |
| 10 | Fidelity Total Market Index Fund | 1,191 | $1K | Feb 2026 |
Valuation
Market Cap
$6.8M
Enterprise Value
$16.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
—
P/S
17.18x
P/FCF
-0.24x
EV/EBITDA
—
Shares Out
15.5M
Financials (TTM)
Revenue
$398K
Net Income
-$28.9M
EBITDA
-$27.8M
Free Cash Flow
-$29.0M
Op Cash Flow
-$28.9M
EPS Basic
$-18.62
EPS Diluted
$-18.62
EPS Forward
$-0.99
Gross Margin
100.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$36.1M
Total Liab.
$46.8M
Total Equity
-$10.7M
Cash
$15.9M
LT Debt
$25.4M
Book Value/Sh
$-0.69
Debt/Equity
-2.82x
Current Ratio
1.71
Quick Ratio
1.71
Returns & Growth
ROE
269.8%
ROA
-80.1%
ROIC
-98.8%
Rev Growth YoY
-74.1%
EPS Growth YoY
-1202.1%
Price Returns
2W
—
1M
-12.0%
3M
-77.9%
6M
-93.6%
12M
-89.8%
Technicals
52W High
$27.58
52W Low
$0.40
50d MA
$1.04
200d MA
$4.53
RSI (14)
44.20
ATR (14)
$0.08
Beta
0.30
Avg Volume
72K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$0.50
High
$0.50
Low
$0.50
Median
$0.50
Data updated apr 28, 2026 2:24pm
· Source: financialmodelingprep.com